QIAGEN's New Diagnostic Races Against the Clock in Sepsis Fight

VENLO, Netherlands – July 14, 2026 – In the high-stakes battle against life-threatening bloodstream infections, the most precious commodity is time. QIAGEN, a global leader in molecular diagnostics, has just deployed a powerful new tool in this fight, launching a rapid diagnostic panel in Europe that can identify deadly bacteria and their resistance to antibiotics in about one hour. The move strengthens the company's position in a fiercely competitive market and provides a much-needed reinforcement for healthcare systems grappling with the twin threats of sepsis and antimicrobial resistance (AMR).

The Gravity of the Hour

Bloodstream infections (BSIs) are a silent and swift killer. When bacteria enter the bloodstream, they can trigger sepsis, a catastrophic immune response that is the leading cause of death in hospitals worldwide. The statistics are staggering: sepsis is linked to an estimated 11 million deaths globally each year, representing nearly one in five of all deaths. For patients who develop septic shock, the most severe form, every hour that passes without effective antibiotic treatment can increase the risk of mortality by as much as 7%.

This grim reality places immense pressure on clinical laboratories, which have traditionally relied on blood culture methods that can take 24 to 72 hours to identify a pathogen and determine which antibiotics will work against it. During this critical waiting period, physicians are often forced to use broad-spectrum antibiotics, a carpet-bombing approach that may be ineffective against a resistant pathogen and contributes to the rise of "superbugs." It is this urgent clinical need—for speed, precision, and actionable intelligence—that defines the battleground for modern diagnostics.

A New Weapon in the Diagnostic Arsenal

QIAGEN's answer is the new CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel. Designed to run on the company's established QIAstat-Dx syndromic testing platform, the panel takes a positive blood culture—the first sign of an infection—and provides a detailed molecular breakdown in roughly 60 minutes. It specifically targets 13 of the most common and dangerous gram-negative bacteria, the culprits behind many of the most difficult-to-treat BSIs, along with 18 genetic markers for antimicrobial resistance.

This new panel complements a previously launched version focused on gram-positive bacteria and fungi. Together, they create a comprehensive BSI testing solution capable of detecting 33 different pathogens and 28 distinct AMR markers. This allows laboratories to provide clinicians with a near-instant, comprehensive view of the enemy they are facing.

“Every hour matters when treating bloodstream infections, particularly when AMR is involved,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Together, our complementary BCID panels provide comprehensive molecular coverage of the pathogens and resistance mechanisms most relevant to bloodstream infections. By delivering results in about one hour, they help laboratories support faster treatment decisions, antimicrobial stewardship and effective infection control.”

The technology integrates sample preparation, analysis, and interpretation into a single automated cartridge, minimizing hands-on time for lab technicians and streamlining workflow. With over 5,200 QIAstat-Dx instruments already placed in more than 100 countries, the infrastructure for deploying this new capability is already widespread.

Navigating a Competitive Diagnostic Landscape

QIAGEN is not operating in a vacuum. The syndromic testing market for infectious diseases is a hotbed of innovation and intense competition. France's bioMérieux is a formidable rival with its widely adopted BIOFIRE® FILMARRAY® BCID panels, which also offer results in about an hour from a positive blood culture. Other key players include DiaSorin and Accelerate Diagnostics, the latter of which offers a unique system that provides phenotypic susceptibility results—showing how a pathogen actually behaves in the presence of an antibiotic—in about seven hours.

Meanwhile, companies like T2 Biosystems are attempting to leapfrog the competition by developing tests that can detect pathogens directly from a blood sample, bypassing the time-consuming blood culture step entirely. While this direct-from-blood approach holds immense promise, its current pathogen menu is more limited.

In this context, QIAGEN's strategy appears focused on providing the most comprehensive, culture-based rapid molecular solution on a single, versatile platform. By offering a broad menu covering respiratory, gastrointestinal, and central nervous system infections in addition to BSIs, the company provides a consolidated system that is attractive to laboratories looking to maximize efficiency. The recent CE-IVDR certification under Europe's new, more stringent regulations is another critical advantage, serving as a seal of quality and a non-negotiable ticket for market access.

Bolstering the Global Fight Against Superbugs

The launch's significance extends far beyond corporate strategy and into the realm of global public health. The World Health Organization has declared AMR one of the greatest threats to humanity. The ability of bacteria to evolve and render our antibiotics useless was linked to nearly 5 million deaths in 2019 alone. QIAGEN's new panel directly addresses this crisis by identifying key resistance mechanisms, such as those that produce extended-spectrum beta-lactamase (ESBL) and carbapenemases, which make infections notoriously difficult to treat.

Armed with this rapid intelligence, clinicians can make two critical moves. First, they can quickly escalate to more powerful, last-resort antibiotics if a highly resistant organism is detected. Second, and just as importantly, they can de-escalate from broad-spectrum drugs to a more targeted, narrow-spectrum antibiotic when the pathogen is found to be susceptible. This second action is the cornerstone of antimicrobial stewardship (AMS), the coordinated effort to preserve the effectiveness of existing antibiotics by using them more judiciously.

By enabling faster, more informed prescribing, technologies like the QIAstat-Dx are not just tools for treating individual patients; they are strategic assets in the long war against microbial evolution. The data generated also feeds into hospital infection control programs and larger public health surveillance networks, helping to track the spread of dangerous pathogens and resistance genes. As the race between medical innovation and microbial adaptation continues, the ability to get the right information to the right hands in a single hour marks a significant advance in our ability to stay ahead.